A Novel Approach to Leveraging the Microbiome Organ

Kaleido Biosciences is a healthcare company with a differentiated, chemistry-driven approach focused on leveraging the potential of the microbiome organ to treat disease and improve human health.
icon2

Human-Centric Discovery & Development

Potential to be faster and more cost efficient

Learn about our proprietary product platform

icon3

Broad Pipeline

Candidates addressing a variety of diseases and conditions with high unmet needs

View our pipeline

icon4

Exceptional Team

Committed to scientific innovation, transforming lives and fostering a strong culture

Join the team

Leadership Team

Alison Lawton

Chief Executive Officer

Alison Lawton has served as Kaleido's Chief Executive Officer, President and as a Director since August 2018, after initially joining the company as our President and Chief Operating Officer in December 2017. Ms. Lawton has more than 30 years of experience in a range of executive and operating roles in the biopharmaceutical industry. Prior to joining Kaleido, she was COO at Aura Biosciences, and previously held the same role at OvaScience in 2013. Ms. Lawton spent more than 20 years at Genzyme Corporation and at Genzyme Sanofi. She served as Senior Vice President and General Manager of Sanofi (Genzyme) Biosurgery, where she was responsible for the surgical, cell therapy and regenerative medicine, and orthopedics franchises. Earlier, as SVP of Global Market Access for Genzyme, Ms. Lawton was involved in leading global functional organizations, including regulatory affairs and quality systems, public policy, health outcomes and strategic pricing, product safety and risk management. Additionally, Ms. Lawton worked for seven years in the U.K. at Warner-Lambert/Parke-Davis. She previously served two terms as the industry representative on the Food & Drug Administration’s Cell & Gene Therapy Advisory Committee and as Chairman of the Board of the Regulatory Affairs Professional Society (RAPS). She is currently an independent Director of ProQR Therapeutics and Verastem, Inc., and was previously a director on the boards of Cubist Pharmaceuticals, CoLucid Pharmaceuticals, and Magenta Therapeutics. She earned her Bachelor of Science degree in Pharmacology from King’s College London.

Joshua Brumm

Chief Operating Officer & Chief Financial Officer

Joshua Brumm has served as Kaleido's Chief Operating Officer and Chief Financial Officer since August 2018, and as our Chief Financial Officer since April 2018. Prior to joining Kaleido, Mr. Brumm was COO and CFO at Versartis, where he oversaw the company’s financial strategy, including the successful completion of a $145 million initial public offering, played an integral role in product strategy, and helped negotiate the company’s first product partnership. Prior to that, he was executive vice president of finance and principal financial officer at Pharmacyclics, and CFO at ZELTIQ Aesthetics, where he also served in corporate development and sales roles. He also was director of finance at Proteolix, Inc., helping in the sale of the company to Onyx Pharmaceuticals. Over the course of his career, Mr. Brumm has raised more than $800 million in equity financings. In 2014, he was named Silicon Valley Business Journal’s CFO of the Year for companies under $500 million. He also held investment banking roles at Citigroup Global Markets, Inc. and Morgan Stanley. He holds a B.A. in Business Administration from the University of Notre Dame.

Katharine Knobil, M.D.

Chief Medical Officer and Head of Research & Development

Katharine Knobil joined Kaleido in December 2018 as Chief Medical Officer and Head of Research & Development. Dr. Knobil spent more than 20 years in roles of increasing responsibility at GlaxoSmithKline (GSK), most recently serving as chief medical officer, overseeing medical affairs, health outcomes, global clinical safety and medical governance across the pharmaceutical, vaccines, and consumer businesses. Previously she was CMO for Pharmaceuticals at GSK from 2015 to 2017, and prior to that was senior vice president, value evidence and outcomes. Dr. Knobil first joined GSK in 1997 as a research physician in respiratory clinical development, and subsequently held a number of roles, including leading the European respiratory clinical team, and building the late-stage clinical development for all therapeutic areas in China. Dr. Knobil was recently named one of 2018's Fiercest Women in Life Sciences by FiercePharma. She has served on the Board of Directors of the National Health Council and has been active with the National Academies of Sciences, Engineering, and Medicine, and the Patient Centered Outcomes Research Institute. Dr. Knobil received her B.A. from Cornell University, her M.D. from University of Texas Southwestern Medical School, and completed a Fellowship in Pulmonary and Critical Care Medicine at the Johns Hopkins Medical School.

Michael Bruce, Ph.D.

Senior Vice President, Development Operations

Michael Bruce, Ph.D. has served as Kaleido's Senior Vice President, Development Operations since August 2018, and previously served as our Senior Vice President, Program, Portfolio, Alliance Management from October 2017 to August 2018. Prior to joining Kaleido, Dr. Bruce served as Senior Vice President, Portfolio Project and Alliance Management at CRISPR Therapeutics from 2015 to 2017. There, he played key roles in building alliances with major biotech and pharmaceutical companies, including acting as Head of Operations of Casebia, a joint venture of CRISPR Therapeutics and Bayer AG. Before joining CRISPR, Dr. Bruce held multiple roles at Pfizer, Inc. and Wyeth from 2003 to 2015, until ultimately serving as Vice President, Development Operations, Worldwide Research and Development. Dr. Bruce holds a B.A. in chemistry from Williams College and a Ph.D. in chemistry from Stanford University.

John W. Davies, Ph.D.

Chief Technology Officer

John Davies, Ph.D. has served as Kaleido's Chief Technology Officer since October 2017. Prior to joining Kaleido, Dr. Davies served as Executive Director, Global Head of In Silico Lead Discovery at Novartis Institutes for Biomedical Research (NIBR), the innovation arm of Novartis AG, from 2012 to 2017. Before that, he held various research positions at NIBR from 1997 to 2012. Earlier in his career, he worked in computational modeling and research at both GlaxoSmithKline and Sandoz. Dr. Davies received his Ph.D. in synthetic organic chemistry from University College London and his B.Sc. in chemistry from the University of East London.

Rob Miller, Ph.D.

Interim President & Chief Scientific Officer, Nutrition

Dr. Miller oversees the consumer product research and development pipeline at Kaleido, following a successful 30 year career at Abbott Nutrition. Miller was responsible for global pediatric, adult, and performance nutrition product development, innovation, new ventures, medical safety, clinical and preclinical research as the Divisional Vice President of R&D, Scientific and Medical Affairs at Abbott Nutrition, and was part of the Executive team managing the $7 billion nutrition business. He was an architect of the global expansion of Abbott Nutrition, establishing R&D Centers in Singapore, Shanghai, China and Bangalore, India. Dr. Miller was co-chair of the Abbott Scientific Governing Board from 2013-2016, overseeing talent development and program efforts of Abbott’s 2,500 scientists for all Abbott Laboratories divisions. He continues to develop leadership potential in scientists through his responsibilities as a Commissioner for the Food Systems Leadership Institute part of the Association of Public and Land Grant Universities. Miller holds a Ph.D. in Nutritional Biochemistry from the University of Wisconsin-Madison, and completed a Staff fellowship at the National Institute of Health.

Wendy Arnold

Senior Vice President, Human Resources

Wendy Arnold has served as Kaleido's Senior Vice President, Human Resources since January 2018. Ms. Arnold brings more than 20 years of experience in human resources to Kaleido, including extensive work in the biopharmaceutical industry. Prior to joining Kaleido, Ms. Arnold was head of the HR business partnership function at Moderna Therapeutics, and helped lead the HR organization during a period of significant growth, including implementing talent and engagement initiatives, compensation framework and benefits program enhancements. Prior to that, she was at Celgene Avilomics Research (formerly Avila Therapeutics) where she was responsible for building and developing the HR infrastructure for the company’s early research and development division. She also held senior HR positions at Inotek Pharmaceuticals and Amylin Pharmaceuticals. Ms. Arnold received her Bachelor of Science degree from Colorado State University.

Susan Stewart, J.D.

Senior Vice President, Regulatory Affairs & Quality

Susan Stewart has served as Kaleido's Senior Vice President, Regulatory Affairs & Quality since April 2018. Ms. Stewart has worked for more than 25 years in biopharmaceutical regulatory affairs, with significant experience devising innovative strategies for novel therapeutics, overseeing regulatory submissions at various stages of product development and leading interactions with global health authorities. Previously, in addition to being an independent regulatory consultant for several years, she was senior vice president of regulatory affairs, quality, and compliance at Tokai Pharmaceuticals and vice president, regulatory affairs at Transmolecular. She also spent more than 10 years at Genzyme Corporation in regulatory and compliance roles, including serving as vice president, regulatory affairs. She received her J.D. from Concord Law School at Purdue University Global and her B.A. from the University of Massachusetts.

Stephen Sofen, Ph.D.

Senior Vice President, Technical Operations

Stephen Sofen, Ph.D. has served as Kaleido's Senior Vice President, Technical Operations since March 2018. Dr. Sofen brings to Kaleido extensive experience in technical innovation, product development and manufacturing, including more than 15 years in the biotechnology industry. Most recently, he was a vice president of technical operations at CRISPR Therapeutics, where he built and led the company’s process development, analytical sciences and manufacturing capabilities. Dr. Sofen also held senior technology and operations positions at Biogen, Genzyme Corporation and the Novartis-MIT Center for Continuous Manufacturing. He received his Ph.D. in bioinorganic chemistry from University of California, Berkley and his B.A. from Reed College.

Jeffery Moore

Senior Vice President of Finance & Administration

Jeffrey Moore has served as Kaleido's Senior Vice President, Finance & Administration since June 2017. Prior to joining Kaleido, he served as Senior Vice President, Finance and Operations and previously as Chief Financial Officer and Treasurer for Axcella Health, Inc., a biotechnology company, from 2011 to 2017. Before that, Mr. Moore served as Chief Financial Officer at Helicos BioSciences Corporation, a life sciences company, from August 2009 to February 2014, and in various other positions at Joule Unlimited Technologies, Inc., BG Medicine, Inc., Affinnova, Inc., and Flagship Ventures. Prior to joining Flagship Ventures, Mr. Moore served as the Director of Business Analysis and Planning at Celera Genomics, and as Vice President, Treasury Operations and Chief Accounting Officer at PerSeptive Biosystems. Mr. Moore started his career with Price Waterhouse in its emerging growth company practice. Mr. Moore received his B.S. degree from Cornell University and an M.B.A. degree from Vanderbilt University.

Geoffrey von Maltzahn

Co-Founder & Chief Innovation Officer

Geoffrey von Maltzahn is a leading innovator and entrepreneur in the microbiome and biotechnology and is a co-founder of companies that have achieved over $3 billion in private and public market capitalization. He is a partner at Flagship Pioneering and has co-founded multiple biotech companies including Seres Therapeutics, Indigo Agriculture, Axcella Health, and Sienna Biopharmaceuticals. Dr. von Maltzahn recently served as the President of Indigo, where he led the creation of the world’s largest plant microbiome database and development of the company’s first commercial products. He is an inventor on more than 100 patents and patent applications in biotech, nutrition and microbiome-based technologies and has been recognized with numerous awards, including the prestigious Lemelson-MIT student prize, given to the most innovative student at MIT. Dr. von Maltzahn’s innovations have been profiled by the Economist, CNN, Fortune, Scientific American, Popular Science and others. He received his PhD from MIT in the Harvard-MIT Division of Health Sciences and Technology.

Michael Bonney

Executive Chair

Mike Bonney is Executive Chair of Kaleido's Board of Directors, and served as CEO from June 2017 until August 2018. Previously, Bonney was CEO and Director of Cubist Pharmaceuticals from 2003 until 2014. Under his leadership, Cubist grew from a struggling micro-cap to the world’s leading antibiotic company, and was acquired by Merck early in 2015 for $9.5 billion. Prior to Cubist, Bonney was Vice President of Sales and Marketing at Biogen where he built the company’s commercial infrastructure for the launch of its first product. Before joining Biogen, he spent 11 years at Zeneca Pharmaceuticals in a range of commercial, operating and strategic roles, ending his career there as National Business Director. Bonney also chairs the boards of Alnylam Pharmaceuticals, Magenta Therapeutics and Bates College. He is a member of a number of other boards, including Celgene Corporation, Sarepta Therapeutics, and Syros Therapeutics. Bonney was a regional winner and national finalist (2013) in the life science segment of Ernst & Young’s Entrepreneur of the Year and was one of six executives nationwide named as Marketwatch’s CEO of the Year (2011). He received his undergraduate degree in economics from Bates College.

Our Mission

Lead a revolution in health by optimizing the human microbiome to:    

  • Redefine the way we treat disease and meaningfully improve health
  • Empower patients, consumers and providers to better manage their health
  • Transform product discovery, development and delivery

Our Culture & Values

We believe we can achieve great things together. Our people and our passion are our greatest strengths. We work as one team – challenging and learning from each other in pursuit of our mission to optimize the human microbiome to lead a revolution in health. We also believe in the importance of enjoying the journey. These values form the foundation of our culture:

Work Together: We value each others’ perspectives and always act with integrity and transparency

Think Bigger, Think Differently: We take risks and challenge the status quo in pursuit of innovation

Learn & Challenge: We learn from success and failure, pushing beyond comfort zones

Keep Commitments: We make commitments and live up to them

Act with Urgency & Excellence: We are relentless in our drive to pursue rigorous science and pioneer new approaches that can transform lives

Working at Kaleido

Kaleido is an exciting place to build your career in a team-focused environment where we challenge and learn from one another.

Watch our video to learn more about the Kaleido difference.